336 related articles for article (PubMed ID: 16544315)
61. Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics.
Grass B; Wachtel M; Behnke S; Leuschner I; Niggli FK; Schäfer BW
Histopathology; 2009 Jun; 54(7):873-9. PubMed ID: 19469909
[TBL] [Abstract][Full Text] [Related]
62. Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells.
Zeng FY; Dong H; Cui J; Liu L; Chen T
Biochem Biophys Res Commun; 2010 Jan; 391(1):1049-55. PubMed ID: 19995556
[TBL] [Abstract][Full Text] [Related]
63. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts.
Wang W; Slevin M; Kumar S; Kumar P
Int J Oncol; 2005 Oct; 27(4):1087-96. PubMed ID: 16142327
[TBL] [Abstract][Full Text] [Related]
64. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.
Davicioni E; Finckenstein FG; Shahbazian V; Buckley JD; Triche TJ; Anderson MJ
Cancer Res; 2006 Jul; 66(14):6936-46. PubMed ID: 16849537
[TBL] [Abstract][Full Text] [Related]
65. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
66. Detection and clinical significance of disseminated tumour cells at diagnosis in bone marrow of children with localised rhabdomyosarcoma.
McDowell HP; Donfrancesco A; Milano GM; Clerico A; Mannarino O; Altavista P; Boldrini R; Cozza R; Inserra A; Dominici C
Eur J Cancer; 2005 Oct; 41(15):2288-96. PubMed ID: 16169716
[TBL] [Abstract][Full Text] [Related]
67. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
Armoni M; Quon MJ; Maor G; Avigad S; Shapiro DN; Harel C; Esposito D; Goshen Y; Yaniv I; Karnieli E
J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
[TBL] [Abstract][Full Text] [Related]
68. Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma.
Du S; Lawrence EJ; Strzelecki D; Rajput P; Xia SJ; Gottesman DM; Barr FG
Int J Cancer; 2005 May; 115(1):85-92. PubMed ID: 15688409
[TBL] [Abstract][Full Text] [Related]
69. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma.
Anderson J; Ramsay A; Gould S; Pritchard-Jones K
Am J Pathol; 2001 Sep; 159(3):1089-96. PubMed ID: 11549601
[TBL] [Abstract][Full Text] [Related]
70. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood.
Wang NP; Marx J; McNutt MA; Rutledge JC; Gown AM
Am J Pathol; 1995 Dec; 147(6):1799-810. PubMed ID: 7495304
[TBL] [Abstract][Full Text] [Related]
71. Clinical relevance of molecular diagnosis in childhood rhabdomyosarcoma.
Tobar A; Avigad S; Zoldan M; Mor C; Goshen Y; Zaizov R
Diagn Mol Pathol; 2000 Mar; 9(1):9-13. PubMed ID: 10718207
[TBL] [Abstract][Full Text] [Related]
72. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
[TBL] [Abstract][Full Text] [Related]
73. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes.
Bridge JA; Liu J; Qualman SJ; Suijkerbuijk R; Wenger G; Zhang J; Wan X; Baker KS; Sorensen P; Barr FG
Genes Chromosomes Cancer; 2002 Mar; 33(3):310-21. PubMed ID: 11807989
[TBL] [Abstract][Full Text] [Related]
74. Mixed embryonal/alveolar rhabdomyosarcoma of the prostate: report of a case with molecular genetic studies and literature review.
Treetipsatit J; Kittikowit W; Zielenska M; Chaipipat M; Thorner PS; Shuangshoti S
Pediatr Dev Pathol; 2009; 12(5):383-9. PubMed ID: 19175284
[TBL] [Abstract][Full Text] [Related]
75. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis.
Graf Finckenstein F; Shahbazian V; Davicioni E; Ren YX; Anderson MJ
Oncogene; 2008 Mar; 27(14):2004-14. PubMed ID: 17922034
[TBL] [Abstract][Full Text] [Related]
76. Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors.
De Pittà C; Tombolan L; Albiero G; Sartori F; Romualdi C; Jurman G; Carli M; Furlanello C; Lanfranchi G; Rosolen A
Int J Cancer; 2006 Jun; 118(11):2772-81. PubMed ID: 16381018
[TBL] [Abstract][Full Text] [Related]
77. Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma.
Fine SW; Lisanti MP; Argani P; Li M
Appl Immunohistochem Mol Morphol; 2005 Sep; 13(3):231-6. PubMed ID: 16082247
[TBL] [Abstract][Full Text] [Related]
78. Detection of FOXO1 break-apart status by fluorescence in situ hybridization in atypical alveolar rhabdomyosarcoma.
Fu L; Jin Y; Jia C; Zhang J; Tai J; Li H; Chen F; Shi J; Guo Y; Ni X; He L
Sci China Life Sci; 2017 Jul; 60(7):721-728. PubMed ID: 28646473
[TBL] [Abstract][Full Text] [Related]
79. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells.
Tsuchiya K; Hosoi H; Misawa-Furihata A; Houghton PJ; Sugimoto T
Int J Oncol; 2007 Jul; 31(1):41-7. PubMed ID: 17549403
[TBL] [Abstract][Full Text] [Related]
80. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
Barr FG
Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
